ArticleAACE endocrinology and diabetes
Pituitary Hyperplasia and Oncocytic Thyroid Neoplasia in a Child With Severe Hypothyroidism.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Severe pediatric hypothyroidism may cause growth failure and pituitary hyperplasia mimicking adenoma. Although thyroid nodules are rare in children, their malignancy risk is higher than in adults. We report a boy with severe hypothyroidism, growth failure, pituitary hyperplasia, and oncocytic thyroid carcinoma, underscoring the need for comprehensive evaluation. Case Presentation: A 10-year-old boy presented with growth delay, height 105 cm (<1st percentile, -6.7 SD), and weight 21.2 kg (third percentile, -2.03 SD). Examination revealed pallor, dry skin, alopecia, Tanner stage I/I, and bitemporal hemianopsia. Laboratory results showed thyroid stimulating hormone >500 mIU/ml (reference 0.45-4.50 mIU/L), free thyroxine <0.30 ng/dl (reference 0.93-1.60 ng/dl), prolactin 102 ng/ml (reference 5-20 ng/ml), and insulin-like growth factor 1 of 8 ng/ml (reference 123-497 ng/ml). Pituitary magnetic resonance imaging demonstrated a homogeneous, isointense sellar lesion with optic chiasma displacement. Thyroid ultrasound showed a 43.9 mm hypoechoic nodule, and fine-needle aspiration classified it as Bethesda category IV. Total thyroidectomy confirmed encapsulated angioinvasive oncocytic carcinoma, followed by radioactive iodine therapy. With levothyroxine and growth hormone treatment, pituitary hyperplasia regressed, and height increased by 15 cm in 1 year. Discussion: Pituitary hyperplasia secondary to hypothyroidism is reversible with levothyroxine and must be differentiated from adenomas to avoid unnecessary surgery. Oncocytic thyroid carcinoma is rare in children, and its coexistence with hypothyroidism is unusual. Conclusion: This case emphasizes the importance of thyroid function testing in children with growth failure and sellar lesions, and vigilance in evaluating pediatric thyroid nodules given their elevated risk of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.